Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes

Diabetes Care. 2016 Dec;39(12):2270-2277. doi: 10.2337/dc16-1594. Epub 2016 Sep 27.

Abstract

Objective: The burden of vascular diseases remains substantial in patients with type 2 diabetes, requiring identification of further risk markers. We tested the absence of dorsalis pedis and posterior tibial pulses as predictors of major macrovascular and microvascular events, death, and cognitive decline in this population.

Research design and methods: Data were derived from 11,120 patients with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) study. Absent peripheral pulses at baseline were defined as absence of at least one dorsalis pedis or posterior tibial pulse.

Results: Absent compared with present peripheral pulses (n = 2,218) were associated with increased 5-year risks for major macrovascular events (hazard ratio 1.47 [95% CI 1.28-1.69], P < 0.0001), myocardial infarction (1.45 [1.13-1.87], P = 0.003), stroke (1.57 [1.23-2.00], P = 0.0003), cardiovascular death (1.61 [1.33-1.95], P < 0.0001), heart failure (1.49 [1.21-1.84], P = 0.0002), all-cause mortality (1.48 [1.29-1.71], P < 0.0001), major microvascular events (1.17 [1.00-1.36], P = 0.04), nephropathy (1.24 [1.00-1.54], P = 0.04), end-stage renal disease or renal death (2.04 [1.12-3.70], P = 0.02), and peripheral neuropathy (1.13 [1.05-1.21], P = 0.0008) after multiple adjustment. Participants with absent dorsalis pedis or posterior tibial pulses had comparable hazard ratios. Risks increased proportionally with the number of absent peripheral pulses, with the highest risks observed in patients with three or four absent pulses. Every additional absent pulse increases the risk of all outcomes.

Conclusions: Absent dorsalis pedis and/or posterior tibial pulses are independent predictors of major vascular outcomes in patients with type 2 diabetes. These simple clinical indicators should be used to improve risk stratification and treatment of these patients.

Trial registration: ClinicalTrials.gov NCT00145925.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Diabetic Angiopathies / diagnosis*
  • Diabetic Angiopathies / drug therapy
  • Diabetic Angiopathies / epidemiology
  • Diabetic Angiopathies / physiopathology
  • Diagnostic Techniques, Cardiovascular
  • Disease Progression
  • Drug Combinations
  • Female
  • Gliclazide / administration & dosage
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Indapamide / administration & dosage
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / drug therapy
  • Kidney Failure, Chronic / physiopathology
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / physiopathology
  • Perindopril / administration & dosage
  • Pulse*
  • Risk Factors
  • Stroke / complications
  • Stroke / diagnosis
  • Stroke / drug therapy

Substances

  • Drug Combinations
  • Hypoglycemic Agents
  • indapamide, perindopril drug combination
  • Indapamide
  • Gliclazide
  • Perindopril

Associated data

  • ClinicalTrials.gov/NCT00145925